Figure 3

IFN-beta-related pathways and gene expression changes in MX1 _low patients during the first month of IFN-beta therapy. The log-2 ratios of the mean gene expression levels before and after 1 month of subcutaneous IFN-beta therapy are shown by the color of the gene nodes. Genes with significant expression changes are labeled in black (P < 0.01). Receptors, transcription factors and ISGs that were elevated in the MX1_high group (n = 7) at baseline (Figure 2) were strongly upregulated under therapy in MX1_low patients (n = 30), whereas TLR9 and IRAK4 were significantly downregulated in this patient group.